TORONTO, Jan. 17, 2018 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) is pleased to announce that it has signed a licensing agreement with Colorado-based MC Brands LLC d/b/a incredibles, a leading producer of cannabis edibles, wellness products and extracts, to provide a complementary suite of medical cannabis products to patients in Florida. Under the terms of the agreement, Liberty will be the exclusive producer and provider of incredibles cannabis products in Florida, subject to receipt of all required approvals from the Florida Department of Health, Office of Medical Marijuana Use.
"Liberty is proud to join forces with incredibles, a reputable, award-winning and experienced medical cannabis company, to offer high-quality and consistently-dosed cannabis products to our Florida patients," said George Scorsis, Liberty's Director and CEO. "With incredibles' large and consistently evolving product assortment, we can now offer a much wider range of medicine delivery options to patients in need." The incredibles products will be produced by Liberty in Florida as regulations permit and new product categories are approved for sale by the Florida Department of Health's Office of Medical Marijuana Use.
The incredibles, incredible Extracts and incredible Wellness products will be available exclusively for sale through Liberty's Cannabis Education Centers. This exciting new product line will complement Liberty's current lineup of brands to be offered to Florida patients, including Aphria and Mary's Medicinals.
"incredibles stands for commitment to consistency, consumer trust and compliance. That is why we've partnered with like-minded industry leaders like Liberty Health Sciences to deliver a great cannabis experience across the country," said Bob Eschino, Founder and President. "There is a strong demand for incredibles' products and we're excited to work with Liberty to deliver our award-winning products to patients in Florida in 2018."
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. ("Liberty") is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
For more information on Liberty please visit www.libertyhealthsciences.com.
About MC Brands LLC
Originally founded by Bob Eschino, Rick Scarpello, Derek Cumings and Joshua Fink in 2010, Medically Correct (whose IP is licensed by MC Brands) has grown into Colorado's highest-volume and most nationally awarded cannabis-infused product manufacturing company. The business' reputation for high-quality extracts and product innovation, and its investment in long-term growth, has solidified MC Brand's' position as an industry leader in American cannabis.
With a combined 30 years in business development and food production expertise, Eschino and Scarpello shared a fundamental goal of bringing professional and consistent edibles to the cannabis marketplace. They're still equally passionate about delivering reliable products focused on product safety, extraction purity, ingredient quality, consistent dosing and compliant packaging.
incredibles' mission is to advocate on behalf of the cannabis industry and help propel it forward. Featuring a full line of THC-infused terpene-rich edibles, incredibles, incredible Wellness and incredible Extracts continue to lead the industry in innovative chocolates, vape pens, extracts and confections with more product lines in development.
For more information please visit www.iloveincredibles.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's future expansion and growth strategies, the expected regulations and approval for sale by the Florida Department of Health's Office of Medical Marijuana Use of the incredibles' products and the Company's expectations in respect of the future growth of medical cannabis as a treatment option in Florida. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
For further information: For Canadian media inquiries, please contact: Matt Salvatore, Edelman, (613) 315-7362, [email protected]; For U.S. media inquiries, please contact: David Schull or Nic Johnson, Russo Partners, (858) 717-2310, [email protected], [email protected]